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Redox-responsive nanoplatform for codelivery of
miR-519c and gemcitabine for pancreatic
cancer therapy
Xiaofei Xin1, Virender Kumar1, Feng Lin1, Vinod Kumar1, Rajan Bhattarai1, Vijaya R. Bhatt2,
Chalet Tan3*, Ram I. Mahato1*

INTRODUCTION

Pancreatic cancer is one of the most chemotherapy-resistant cancers and a leading cause of cancer-related mortality with a dismal
5-year survival rate of 8 to 10% (https://seer.cancer.gov/statfacts/
html/pancreas.html). Gemcitabine (GEM) is a first-line therapy for
pancreatic cancer either alone or in combination with other drugs
such as nanoparticle albumin-bound paclitaxel or nab-paclitaxel (1).
However, the clinical effect of single-agent GEM is modest due to
its rapid metabolism, inefficient delivery to the desmoplastic tumor,
and development of chemoresistance (2, 3). The combination therapy
of GEM and nab-paclitaxel versus GEM alone increases survival
along with an increase in grade 3 neutropenia, fatigue, and neuro
pathy (4). The use of FOLFIRINOX (5-fluorouracil, oxaliplatin,
irinotecan, and leucovorin combination), as compared to GEM,
significantly prolongs survival but at the expense of higher grade 3
or 4 toxicities (5).
Most patients with pancreatic cancer are present with metastatic
or inoperable disease, and therefore, systemic polychemotherapy
remains the treatment of choice. The median survival of patients
with metastatic pancreatic cancer is still less than a year with either
FOLFIRINOX or GEM and nab-paclitaxel (6, 7). Therefore, safer
and more effective combination of GEM and novel drugs further
need to be developed particularly for older or less fit patients or
those with significant comorbidities, who cannot tolerate intensive
chemotherapy.
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Chemotherapy resistance in pancreatic cancer involves multiple
mechanisms. GEM-resistant cells mainly represent cancer stem cells
and epithelial-to-mesenchymal transformation (EMT) phenotype
(8, 9). Desmoplasia produces hypoxic microenvironment, stimulating hypoxia-inducible factor-1 (HIF-1), which, in turn, modulates
tumor metabolism, induces profibrotic and angiogenic responses, and
mediates the overexpression of adenosine triphosphate–binding
cassette superfamily G member 2 (ABCG2). As a member of the
ABC transporter superfamily, ABCG2 functions as a drug efflux
pump and has been reported to play a role in GEM resistance in
pancreatic cancer (10, 11). Because of an increase in high-glucose
metabolism in GEM-resistant cells, the flux of glycolytic intermediates is directed toward nonoxidative pentose phosphate pathway
(PPP), leading to an increase in pyrimidine biosynthesis and pool of
deoxycytidine triphosphate (dCTP). The structural similarity between dCTP and GEM, a nucleoside analog, results in a molecular
competition to bind the replicating DNA, reducing the efficacy of
GEM. Hypoxia is responsible for an increase in sonic hedgehog (SHH)
signaling and smoothened (SMO) expression in pancreatic cancer and
activation of the transcription factor glioma-associated oncogene (GLI)
(12). These changes result in further generation of fibrosis and a decrease
in blood flow, creating a desmoplasia-hypoxia vicious cycle.
MicroRNAs (miRNAs) regulate gene expression by the degradation of target mRNAs, repressing of mRNA translation, or up-
regulating of target genes. Aberrant expressions of miRNAs correlate
with altered expression of genes responsible for stemness, metastasis,
tumor metabolism, hypoxia, and chemoresistance (13). We previously
reported differential down-regulation of miR-205 and miR-let7b in
human pancreatic cancer tissues and cells (14). Further, we demonstrated that the combination of GEM-conjugated polymeric micelles
and miR-205 significantly inhibited pancreatic tumor growth in
mice after systemic administration, as miR-205 sensitized resistant
pancreatic cells to GEM (8, 15). miR-519c is of particular interest in
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Desmoplastic and hypoxic pancreatic cancer microenvironment induces aberrant expression of miRNAs and
hypoxia-inducible factor-1 (HIF-1) responsible for gemcitabine (GEM) resistance. We demonstrated that miR-519c
was down-regulated in pancreatic cancer and transfection of miR-519c in GEM-resistant pancreatic cancer cells
inhibited HIF-1 level under hypoxia. We synthesized redox-sensitive mPEG-co-P(Asp)-g-DC-g-S-S-GEM polymer,
with GEM payload of 14% (w/w) and 90% GEM release upon incubation with l-glutathione. We synthesized mPEGco-P(Asp)-g-TEPA-g-DC for complex formation with miRNA. Chemical modification of miR-519c with 2′-O-methyl
phosphorothioate (OMe-PS) at 3′ end enhanced its stability and activity without being immunogenic. Epidermal
growth factor receptor targeting peptide GE11 decoration increased tumor accumulation of micelles after systemic administration and significantly inhibited orthotopic desmoplastic pancreatic cancer growth in NSG mice
by down-regulating HIF-1 and genes responsible for glucose uptake and cancer cell metabolism. Our multifunctional nanomedicine of GEM and OMe-PS–miR-519c offers a novel therapeutic strategy to treat desmoplasia and
hypoxia-induced chemoresistance in pancreatic cancer.
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miR-519c inhibits HIF-1, Hh signaling, and tumor
cell invasion
miR-519c was significantly down-regulated in pancreatic cancer
tissue compared to adjacent normal tissues, as determined by real-
time reverse transcription polymerase chain reaction (RT-PCR)
(Fig. 1A). Similarly, we observed a significantly low miR-519c expression level in pancreatic cancer cell lines such as HPAF-II,
Capan-1, and MIA PaCa-2R, compared to nonmalignant pancreatic
cells HPDE (human pancreatic duct epithelial) (Fig. 1B). With target
prediction by miRTarBase, we confirmed that miR-519c directly
targets HIF-1 and ABCG2, indicating its potential utility to reverse
hypoxia-induced chemoresistance.
Expression of SHH, SMO, and GLI1 was significantly higher under
hypoxic versus normoxic conditions, as determined by Western blot
analysis. Transfection of pancreatic cancer cells with Lipofectamine/
miR-519c complexes significantly inhibited the expression of HIF1 and Hh ligands, such as SHH, GLI1, and SMO (Fig. 1, C and D).
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Overexpression of HIF-1 in patient pancreatic cancer
tissues and cell lines
We first established a GEM-resistant pancreatic ductal adenocarcinoma (PDAC) cell model by incubating wild-type MIA PaCa-2 cells
with increasing concentrations of GEM over 2 months. The resulting GEM-resistant MIA PaCa-2R cells were 25-fold more resistant
compared to the wild-type MIA PaCa-2 cells, as reflected by the
pronounced increase in the median inhibitory concentration value
from 2 to 50 M. Our immunohistochemical analysis demonstrated
a high expression of HIF-1 protein in patient-derived pancreatic
cancer tissues but a negligible expression in adjacent healthy patient
tissues (fig. S1A). Western blot analysis of MIA PaCa-2R cells
demonstrated that the expression level of HIF-1 was very low
under normoxic conditions but significantly increased, reaching
the highest level at 4 hours after incubation of MIA PaCa-2R cells
under hypoxic condition (fig. S1B).
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Fig. 1. miR-519c expression is down-regulated in pancreatic cancer, and its overexpression inhibits HIF-1, Hh signaling, and cell migration under hypoxic
condition. miR-519c was down-regulated in patient tissues (A) and pancreatic cancer cell lines (B), compared to paired normal tissues and normal pancreatic cells such
as HPDE. Further, miR-519c inhibited the expression of HIF-1 and Hh ligands such as SHH, SMO, and GLI1 after the transfection of MIA PaCa-2R cells with Lipofectamine/
miR-519c under hypoxic condition (C and D). (E) miR-519c also inhibited cell migration under hypoxic condition when MIA PaCa-2R cells were cultured on Transwell
chamber with human pancreatic stellate cells (hPSCs). *P < 0.05, two-paired t test.
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pancreatic cancer, as it is down-regulated in pancreatic cancer, binds
to HIF-1 mRNA, and can inhibit HIF-1 expression, leading to
sensitization of pancreatic cancer cells (16, 17). We hypothesize that
a combination of GEM and miR-519c can target HIF-1 and ABCG2,
resensitize resistant pancreatic cancer cells to GEM, and result in
decreased desmoplasia. Moreover, 2′-O-methyl phosphorothioate
(2′-OMe-PS) modification of RNA based on our previous study
(18) was applied to miR-519c to increase its stability, binding affinity,
and functional potential and decrease immunostimulatory properties.
Nanoparticulate delivery systems have shown distinct advantages
in increasing drug accumulation at the tumor site after systemic
administration. GEM delivery is limited by its poor pharmacokinetic
profiles and dense desmoplasia, which may be overcome by a
GEM-conjugated delivery system. We recently developed methoxy
poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene
carbonate)-graft-gemcitabine-graft-dodecanol (mPEG-b-PCC-g-GEMg-DC), which conjugates GEM via stable amide bonds and self-assembles
into micelles, with 12% (w/w) GEM loading and 2.5-fold higher
GEM accumulation in orthotopic pancreatic cancer compared to
free GEM (2). Redox-sensitive polymeric micelles are very promising due to their controlled drug release inside the tumor cells in the
presence of intracellular stimuli, including glutathione (GSH) (19).
GSH concentration in tumor cells is several times higher than that
in the extracellular microenvironment and normal tissues (20). Epidermal growth factor receptor (EGFR) has been overexpressed in 40
to 80% of pancreatic cancers. Cells that overexpress EGFR will accumulate the functionalized particles, resulting in greater cytotoxicity.
We hypothesized that EGFR targeted GE11 peptide mixed micelles
system based on tetraethylene pentamine (TEPA) for complex
formation with miRNA and GSH-sensitive polypeptide for GEM conjugation via disulfide bond for targeted delivery of GEM and OMePS–miR-519c will result in a synergistic inhibition of pancreatic cancer
without excess toxicity. Our in vitro and in vivo studies confirmed
that mixed OMe-PS–miR-519c–complexed and GEM-conjugated
mixed micelles effectively inhibit pancreatic tumor growth.
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We observed that addition of human pancreatic stellate cells (hPSCs)–
conditioned medium to MIA PaCa-2R cells induced tumor cell invasion, especially under hypoxic condition (Fig. 1E), indicating that the
exposure of MIA PaCa-2R cells to desmoplastic microenvironment
enhances their invasion capacity. Additional treatment of MIA PaCa-
2R cells with miR-519c inhibited cell migration under hypoxic condition and desmoplasia (Fig. 1E).
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miR-519c sensitizes hypoxic GEM-resistant tumor cells
to cell killing by GEM
Because of an increase in high-glucose metabolism in GEM-resistant
cells, the flux of glycolytic intermediates is directed toward nono
xidative PPP, leading to an increase in pyrimidine biosynthesis and
pool of dCTP. As GEM is a nucleoside analog, its efficacy is affected
by both nucleoside synthesis and their cellular uptake. The presence
of dC resulted in a dose-dependent decrease in cytotoxicity after
treatment with GEM (Fig. 3A), suggesting that treatment with dCTP
increased GEM resistance in MIA PaCa-2R cells. The combination
of miR-519c and GEM demonstrated a dose-dependent synergistic
effect on cell killing. In contrast, treatment with scrambled miRNA
had little effect on cell killing (Fig. 3B). Apoptosis assay further confirmed these observations (fig. S3A). The effect of miR-519c on cell
cycle of MIA PaCa-2R cells was determined by flow cytometry after
the transfection of MIA PaCa-2R cells with miR-519c under normoxic
and hypoxic conditions. Treatment with miR-519c compared to
scrambled miRNA under hypoxic conditions resulted in a significant increase in the percentage of cells in the G2 phase (Fig. 3C and
fig. S3A). These data suggest that miR-519c inhibited pancreatic
cancer cell proliferation by inducing G2 phase cell cycle arrest.
The Western blot analysis demonstrated that drug resistance–
related protein ABCG2 and transcription factor c-MYC (which
promotes cancer cell proliferation) and programmed death-ligand
1 (PD-L1) were up-regulated under hypoxic condition. These data
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Fig. 2. miR-519c inhibits glucose metabolism to inhibit GEM resistance to pancreatic cancer cells under hypoxic condition. (A and B) miR-519c inhibited 2-DG uptake, as
well as expression of GLUT1 and dCTP, but not scrambled miRNA under hypoxic condition after transfection of MIA PaCa-2R cells with Lipofectamine miR-519c. Cells transfected
with Lipofectamine/scrambled miRNA complexes were used as the control. (C) miR-519c decreased dCTP level under hypoxic condition. (D) In addition, miR-519c but not scrambled miRNA inhibited NME4, HKII, LDHA, and TKT expressions under hypoxic condition. Results are presented as the mean ±SD (n = 3). *P < 0.05 and **P < 0.001, two-paired t test.
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miR-519c inhibits glucose influx and metabolism
under hypoxia
Flow cytometry data demonstrated an up-regulation of glucose
transporter 1 (GLUT1) expression in MIA PaCa-2R cells under
hypoxic conditions. Transfection of these cells with miR-519c, but
not scrambled miRNA, significantly inhibited GLUT1 expression
under hypoxic conditions (Fig. 2A and fig. S2). As a glucose analog,
the uptake of 2-deoxyglucose (2-DG) by MIA PaCa-2R cells was
significantly increased under hypoxic conditions even when these
cells were transfected with scrambled miRNA. This is expected, as
GLUT1 is a well-known HIF-1 target. Transfection of these cells with
miR-519c resulted in a significant decrease in 2-DG uptake under
hypoxic conditions (Fig. 2B), suggesting that miR-519c negates
hypoxia-induced elevation in glucose uptake, using 2-DG as a GLUT1
substrate. The concentration of dCTP was significantly higher under
hypoxic conditions but declined following the transfection of MIA
PaCa-2R cells with Lipofectamine/miR-519c complexes (Fig. 2C),
indicating that the intracellular level of dCTP is severely suppressed
by miR-519c. Hypoxia is known to increase glycolytic influx and
pyrimidine biosynthesis in tumor cells. The mRNA expression levels of several known targets of HIF-1 were up-regulated under the
hypoxic condition. These targets included NME/NM23 nucleoside
diphosphate kinase (NME4) involved in PPP and nucleotide biosynthesis pathways, as well as lactate dehydrogenase (LDH), hexo

kinase 2 (HKII), and transketolase (TKT) involved in glucose
metabolism. The expression level of these targets genes was significantly inhibited after the transfection of MIA PaCa-2R cells with
miR-519c but not by scrambled miRNA (Fig. 2D). Together, these
results provide strong evidence that miR-519c repletion attenuates
glucose metabolism and reduces intracellular dCTP pool.
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Fig. 3. miR-519c and GEM synergistically inhibit pancreatic cancer cell proliferation and promote apoptosis. (A) Coincubation of GEM with 100 M dC-reduced
drug potency. (B) Significant decrease in cell viability when MIA PaCa-2R cells were transfected with a combination of GEM and miR-519c under the hypoxic condition for
48 hours, but GEM combination with scrambled miRNA was less effective. (C) miR-519c inhibited viability by arresting cell cycle in the G2-M phase. (D and E) miR-519c
inhibits ABCG2, c-Myc, and programmed death-ligand 1 (PD-L1) expressions, which are up-regulated under hypoxic condition, but scrambled miRNA had little effect.
(F) Combination of miR-519c and GEM was more effective in apoptotic cell death of tumor spheroids generated using MIA PaCa-R cells than either of them alone. The
confocal laser scanning microscopy images were captured at a depth of 15 m. *P < 0.05 and **P < 0.001, two-paired t test.

indicated that the hypoxic-dependent up-regulation of ABCG2- and
c-MYC–magnified GEM resistance and PD-L1 can promote immune
escape of tumor cells from cytotoxic T lymphocytes and contribute
to the immunosuppression in tumors under hypoxia. Then, the
apoptosis rate was investigated by the coculturing of MIA PaCa-2R
and peripheral blood lymphocytes with or without miR-519c treatment under normoxic and hypoxic conditions (fig. S4). We observed
a significant increase in apoptosis of MIA PaCa-2R cells in the coculture system with miR-519c transfection under hypoxia. Treatment
of MIA PaCa-2R cells with miR-519c but not scrambled miRNA inhibited expression of ABCG2, c-MYC, and PD-L1 (Fig. 3, D and E).
These data suggest that miR-519c has the potential to improve the
cytotoxicity of activated T cells and immunotherapy.
Three-dimensional (3D) desmoplastic tumor spheroids were developed to mimic the hypoxic microenvironment in pancreatic cancer
by mixing and culturing hPSCs and MIA PaCa-2R cells in hanging
drop plates. Live and dead assay was carried out after treatment with
miR-519c and GEM for 48 hours by confocal laser scanning micros
copy. Fluorescein isothiocyanate–labeled calcein and propidium
iodide binding to nucleic acids presented live and dead cells, respectively. Treatment with the combination of miR-519c and GEM for
9 days exhibited a significantly higher inhibition of tumor growth,
leading to the collapse of tumor spheroids. In contrast, treatment
with miR-519c or GEM alone failed to destroy tumor spheroids
(Fig. 3F). These results suggest that miR-519c facilitates the resensitization of pancreatic cancer cells to GEM.
Chemical modification with OMe-PS increases the stability
and targeting efficiency of miR-519c without eliciting
proinflammatory response
Chemical modifications can protect miRNA against nuclease degradation and affect their nonspecific interaction with plasma proteins
Xin et al., Sci. Adv. 2020; 6 : eabd6764
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and cell membrane components. Therefore, modification of its 3′
end with OMe-PS stabilized miR-519c, which in good agreement
with our previous study (18). We determined the effect of nucleases
on miRNA stability by incubating unmodified miR-519c and OMePS–miR-519c in 50% fetal bovine serum (FBS). miR-519c was
degraded within an hour in 50% FBS at 37°C. When three-terminal
nucleotides at the 3′ end of miR-519c guide strand were modified,
with 2′-OMe-PS, its stability was substantially increased, resulting
in significant levels of intact miRNA remained even after 24 hours
of incubation at 37°C (Fig. 4A). Further, there was no loss of activity
in cell killing due to this chemical modification. Incubation of MIA
PaCa-2R cells with the combination of 100 nM OMe-PS–miR-519c
or miR-519c and increasing concentrations of GEM demonstrated
a dose-dependent synergistic effect on cell killing, with OMe-PS–
miR-519c being more potent than miR-519c (Fig. 4B).
To examine whether the chemical modification of miR-519c
induces proinflammatory cytokine production, we determined the
levels of interleukin-2 (IL-2) and IL-4 after incubating OMe-PS–
miR-519c and unmodified miR-519c with human peripheral blood
mononuclear cells (hPBMCs) for 24 hours and measured cytokines
released in hPBMC cultures using a cytokine multianalyte ELISArray
kit. The antigen standard cocktail was added to the plate as the positive control. There was a little induction of cytokines due to miRNA
treatment. Compared to miR-519c–treated groups, OMe-PS–miR519c–treated hPBMCs showed the lower release of cytokines, including IL-2 and IL-4 (Fig. 4, C and D).
Argonaute 2 (AGO2) protein is a ribonuclease (RNase) and is an
essential component of the RNA-induced silencing complex (RISC)
where one strand of the mature miRNA duplex is first loaded onto
AGO2 protein. AGO2-bound miRNA interacts with complementary
regions of target mRNA and leads to either AGO2-mediated endonuclease cleavage of the mRNA or reduction in its translation
4 of 14
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efficiency. Therefore, we assessed the effect of chemical modification of miR-519c on its association with AGO2 compared to unmodified miR-519c and OMe-PS–miR-519c in the cytoplasm. As
shown in Fig. 4E, the transfection of MIA PaCa-2R with miR-519c
and OMe-PS–miR-519c was resulting in 3- and 16-fold higher RISC
loading than that of the control group. Consequently, higher RISC
loading resulted in improved inhibition of HIF-1 and ABCG2
(Fig. 4F). Notably, the AGO2 association did not differ between
normoxic and hypoxic conditions.
Redox-sensitive nanocarriers achieve combined delivery
of OMe-PS–miR-519c and GEM
On the basis of the results above, we selected OMe-PS–miR-519c
over miR-519c for in vivo studies due to its higher stability, enhanced RISC loading, and affinity. We used our mPEG-co-P(Asp)g-TEPA-g-DC cationic copolymer for complex formation with
miRNA and used for preparing mixed micelles with mPEG-coP(Asp)-g-Ala-SS-GEM-g-DC for codelivery of OMe-PS-miR-591c
and GEM. 1H nuclear magnetic resonance (NMR) of mPEG-coP(Asp)-g-TEPA-g-DC and mPEG-co-P(Asp)-g-Ala-SS-GEM-g-DC
is shown in Fig. 5 (A and B). The percentage of GEM loading in
mPEG-co-P(Asp)-g-Ala-SS-GEM-g-DC was calculated to be 14%
on the basis of the integration of peak at 3.5 parts per million (ppm)
for the CH2 of mPEG (f) and peaks at 7.8 to 8.22, 7.09, 5.29 to 6.16,
4.36, 4.27, 3.0, and 2.93 ppm (a, b, c, d, e, g, and h), respectively
(protons on GEM-S-S-NH2). The rest of the carboxylic acid groups
in the polymer were also reacted with dodecylamine (DC) to provide
sufficient hydrophobicity for micelle formation, as indicated by the
peaks at 0.85, 0.98, and 1.23 ppm (i, j, and k), respectively. In TEPA
polymer, the broad peak at 2.98 ppm for TEPA and the characteristic
peaks at 1.38, 1.24, and 0.85 ppm (e, f, and g) for DC chain suggest their
successful conjugation (Fig. 5B). 1H NMR spectra of intermediate prodXin et al., Sci. Adv. 2020; 6 : eabd6764

11 November 2020

ucts, such as mPEG-PBLA (Poly--benzyl-L-aspartate) in dimethyl
sulfoxide (DMSO)–d6, Boc-Ala-SS-OH in CDCl3, Diboc-GEM in
DMSO-d6, Boc-Ala-SS-Diboc-GEM in CDCl3, Ala-SS-GEM in DMSO-d6,
and GE11-PEG-co-P(Asp)-g-DC in DMSO-d6, are also shown in fig. S5.
The particle size distribution of miR-519c–complexed and GEM-
conjugated redox-sensitive mixed micelles was prepared using mPEGco-P(Asp)-g-Ala-SS-GEM-g-DC and mPEG-b-PCC-g-DC-g-TEPA
(Fig. 5C). As determined by atomic force microscopy, these mixed
micelles were spherical in shape and narrow particle size distribution, with the mean particle size of 129.5 ± 5 nm (Fig. 5D). GEM
loading was 14% in the polymer conjugate, as determined after
alkaline hydrolysis and analysis with high-performance liquid
chromatography–ultraviolet (HPLC-UV), which was consistent with
the NMR calculation. Micelles prepared using mPEG-co-P(Asp)-gTEPA-g-DC had the mean particle size of 77.18 nm and formed a
complex with miRNA at a very low N:P ratio (4:1) (fig. S6). The
particle size of mixed micelles based on the above two polymers was
160 nm. Drug-polymer conjugates and miRNA were analyzed for
their drug release profiles at different conditions. In the absence of
GSH, GEM conjugates were stable and released only up to 5% of
GEM within 4 days. Disulfide conjugates released significant amounts
of GEM within an hour in 10 mM GSH. These results confirmed
that disulfide conjugates were stable at physiological conditions but
rapidly released GEM in the reducing environment. The release
profile demonstrated a controlled release of miRNA from GEM
conjugates/TEPA micelles over 2 days (Fig. 5F).
EGFR-targeted nanocarriers effectively deliver GEM
and OMe-PS–miR-519c to desmoplastic pancreatic tumor
in an orthotopic mouse model
To optimize GE11 peptide concentration for enhanced EGFR receptor–
meditated endocytosis, we determined the effect of GE11 peptide on
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Fig. 5. Conjugation of GEM to redox-sensitive polymer via disulfide bond demonstrates rapid GEM release in the presence of GSH but negligible GEM release
in the absence of GSH at pH 7.4. (A and B) 1H NMR spectra of mPEG-co-P(Asp)-g-TEPA-g-DC and mPEG-co-P(Asp)-g-Ala-SS-GEM-g-DC. (C) Particle size distribution of
redox-sensitive mixed micelles, as determined by dynamic light scattering. (D) Surface morphology and particle size distribution of mixed micelles determined by atomic
force microscopy. (E) mPEG-co-P(Asp)-g-TEPA-g-DC forms complexes with miRNA at the N:P (TEPA:miRNA) ratio of 4:1 and above, as determined by gel electrophoresis.
(F) GEM and miRNA release profiles from micelles with or without miR-519c demonstrate GSH-responsive GEM release and controlled release of miRNA in the presence
of GSH.

the cellular uptake of micelles after incubation of MIA PaCa-2R
cells with coumarin G6–loaded mixed micelles prepared at 10:90,
20:80, and 30:70 ratios of GE11 peptide–decorated micelles and
nontargeted micelles. There was an increase in cellular uptake with
increasing GE11 peptide concentration, but the level of cellular
uptake for the mixed micelles at 20:80 and 30:70 ratios was similar
(fig. S7A). To avoid the effect of high GE11 peptide concentration
on micellar stability and systemic toxicity, we did not formulate
targeted micelles beyond 30:70 ratio. Preincubation of cells with
excess of free GE11 peptide significantly reduced the cellular uptake
of the mixed micelles, indicating that the uptake was receptor mediated (fig. S7A). Then, we determined the biodistribution of GEM
to the tumor at 6 and 24 hours after systemic administration of
nontargeted and EGFR-targeted GE11-decorated GEM-conjugated
OMe-PS–miR-519c mixed micelles into desmoplastic pancreatic
tumor–bearing nonobese diabetic/severe combined immunodeficient–
gamma null (NSG) mice at the doses of GEM (20 mg/kg) and miRNA
(1 mg/kg). Desmoplastic orthotopic mouse model recapitulates
hypoxic tumor microenvironment responsible for decreased drug
delivery and chemoresistance in pancreatic cancer. At 6 and 24 hours
after administration, GEM and miRNA were extracted from the tumor,
and the liver and their concentrations were determined by liquid
chromatography–tandem mass spectrometry (LC-MS/MS) (using
5-Aza-2′-dC as an internal standard) and real-time PCR, respectively. We observed significantly higher GEM and miR-519c concentrations in the tumor at 6 and 24 hours after administration of
GE11 peptide–decorated combination mixed micelles compared to
nontargeted combination mixed micelles (Fig. 6A). In contrast,
GEM concentrations in the liver at 6 and 24 hours after administration of GE11 peptide–decorated combination mixed micelles were
Xin et al., Sci. Adv. 2020; 6 : eabd6764
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significantly lower than those of the mice injected with nontargeted
combination mixed micelles (fig. S8A). The relative levels of miR519c were higher in the tumor at 6 and 24 hours after administration
of GE11 peptide–decorated combination mixed micelles compared
to nontargeted combination mixed micelles (fig. S8C).
Combination therapy of GEM and OMe-PS–miR-519c via
EGFR-targeted nanocarriers exerts superior efficacy against
orthotopic pancreatic tumor growth
Desmoplastic orthotopic mouse model recapitulates hypoxic tumor
microenvironment responsible for decreased drug delivery and
chemoresistance in pancreatic cancer. Micelles were injected intravenously three times a week for 2 weeks, and tumor growth was
monitored by in vivo imaging system (IVIS) bioluminescence
imaging. The rationale of doses and schedules of individual drugs
were designed on the basis of previous studies (21). Notably, the
combination therapy had lower doses of individual drug and
miRNA. GEM micelles and OMe-PS–miR-519c micelles separately
controlled tumor growth significantly more than saline or free GEM.
Nontargeted combination micelles demonstrated synergy and had
greater tumor growth inhibition than either GEM-conjugated
micelles or OMe-PS–miR-519c–complexed micelles, reflecting the
ability of OMe-PS–miR-519c to down-regulate HIF-1 and resensitize pancreatic cancer to GEM. EGFR-targeted GE11 peptide–
decorated mixed micelles were even more effective than nontargeted
mixed micelles in controlling tumor growth (Fig. 6B). The tumor
weight was the lowest for GE11 peptide–decorated combination
micelles–treated group compared to all treated groups (Fig. 6C).
We did not observe a decrease in body weight or morbidity in mice
(Fig. 6D).
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Hematoxylin and eosin (H&E) staining of tumor tissues confirmed
the extensive apoptotic and necrotic cells throughout the tumor in
the control group and the inhibition of proliferation of tumor cells
in the treated groups. Compared to the control and free GEM
Xin et al., Sci. Adv. 2020; 6 : eabd6764

11 November 2020

group, the tumor samples from GEM conjugated redox-sensitive
micelles–treated group exhibited with limited metastatic cells (Fig. 6E).
Coinjection of hPSCs with MIA PaCa-2R cells stimulated tumor
growth by inducing fibrosis, as evidenced by the overexpression of
7 of 14
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DISCUSSION

PDAC is a recalcitrant disease characterized by highly aggressive
cancer cells, extensive desmoplastic reaction, and hypovascularization. These unique features endow PDAC tumors with an array of
resistance mechanisms against standard-of-care chemotherapy treatments (22). It is, therefore, urgent to identify novel targets that can
sensitize tumor cells. Desmoplastic and hypoxic pancreatic tumor
microenvironments play multifaceted roles in inducing chemotherapy
resistance, promoting distant metastasis, and serving as a barrier to
drug delivery (23). Hypoxic microenvironment activates quiescent
PSCs in extracellular matrix (ECM) by up-regulation of Hh signaling ligands (Fig. 1D). Strong desmoplasia severely affects vascular
function, resulting in hypovascularization of the tumor, which
up-regulates HIF-1 expression (fig. S1). Therefore, a cycle of hypoxia and desmoplasia is amplifying each other. This cycle could be
blocked by HIF-1 inhibition, which was found sufficient enough
to impede Hh signaling (24).
Aberrant expression of miRNA correlates with altered expression
of genes responsible for stemness, metastasis, cancer metabolism,
hypoxia, and chemoresistance (25). The advantage of miRNAs lies
in their ability to modulate multiple cellular pathways simultaneously,
which are difficult to target by small molecules and therapeutic proteins. miR-519c is down-regulated in pancreatic cancer patient tissues and different cell lines (Fig. 1, A and B) but can target HIF-1
and Hh ligands such as SHH and GLI, as determined by Western
blotting (Fig. 1, C and D). Therefore, miR-519c could be a promising strategy in the inhibition of desmoplasia of pancreatic cancer
and other hypoxia-related genes. The presence of miR-519c prevented
Xin et al., Sci. Adv. 2020; 6 : eabd6764
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migration of MIA PaCa-2R cells in the presence of hPSC-conditioned
medium (Fig. 1E), indicative of miR-519c–mediated inhibition of
tumor cell–stromal metabolic interactions. The tumor microenvironment promotes the interactions between cancer cells and their
surrounding cancer-associated fibroblasts (CAFs; PSCs in this case).
This feedback is reciprocal, and CAFs can both promote and impair
cancer progression, while cancer cells promote PSC activation, proliferation, migration, and ECM remodeling capability via the Hh
pathway. Activated PSCs secrete numerous growth factors including platelet-derived growth factor, transforming growth factor–,
and inflammatory cytokines in the tumor (26). Many reports suggest that HIF-1 induces migration in pancreatic cancer cells by
regulating genes such as EMT regulators Snail, chemokine (C-X3-C
motif) receptor 1 (CX3CR1), and glucose metabolism (27, 28). We
have shown that inhibiting HIF-1 decreased several metabolism-
related genes such as GLUT1, NME4, LDHA, HKII, and TKT (Fig. 2,
A and D), thus providing the rationale for reduced migration of
MIA PaCa-2R cells in the presence of miR-519c.
Resistance to chemotherapeutic drugs in pancreatic cancer could
have many causes, such as intrinsic resistance mechanisms and desmoplastic microenvironments that promotes cancer cell resistance
by providing an environment that hampers drug delivery. HIF-1–
mediated metabolic alterations that facilitate GEM resistance in
pancreatic cancer cells have been recently reported (29). GEM-
resistant pancreatic cancer cells maintain a higher dC pool. Increased
glucose metabolism fuels GEM resistance in pancreatic cancer cells,
supporting de novo synthesis of dC through nonoxidative PPPs.
Here, we show that GEM resistance in hypoxic pancreatic cancer
cells can be reversed by miR-519c repletion. The coordinated transcription induction of genes encoding glycolytic enzymes and pyrimidine synthesis in response to hypoxia is mediated by HIF-1.
Consistent with HIF-1 down-regulation by miR-519c, we found
that miR-519c may counteract hypoxia-induced increase in glycolytic influx and intracellular dCTP level (Figs. 2 and 3).
Hypoxia up-regulates glucose metabolism, angiogenesis, and drug-
resistant genes (30). HIF-1 signaling transactivates a multitude of
target genes that enhance glucose uptake, as determined by an increase in 2-DG (Fig. 2B), glycolysis, and oxidative phosphorylation,
thus facilitating cancer cell survival under oxygen- and glucose-
deprived microenvironments. HIF-1 also results in an increase
in pancreatic cancer, leading to increased dCTP pool and GEM resistance (Figs. 2D and 3A). Hypoxia and overexpression of HIF-1
ultimately promote induction of an invasive and treatment-resistant
phenotype of pancreatic cancer.
We have reported previously that under in vitro conditions, GEM
is highly effective in mediating toxicity against human pancreatic
cancer cells. In contrast, orthotopic tumors in the pancreas were
resistant to systemic therapy of GEM. Many factors affect GEM
efficacy in vivo, including higher-rate metabolism, dose-limiting
toxicity, competition with cellular dCTP pool, various efflux mechanisms, and poor penetration into the bulk of the tumor.
ABCG2 is an efflux transporter that is often observed in drug-
resistant cancer cells and contributes to a multidrug resistance
phenotype. ABCG2 may help provide a survival advantage during
conditions of hypoxia and allow cells to escape the toxic effects
of chemotherapeutic drugs. HIF-1 binds to the hypoxia response
element, and binding of latter to the ABCG2 promoter increases its
transcription in pancreatic cancer cells (31). Our data suggest that
miR-519c, by inhibiting HIF-1, decreases ABCG2-mediated GEM
8 of 14

Downloaded from http://advances.sciencemag.org/ on March 10, 2021

–smooth muscle actin (-SMA) in the tumor of the saline-treated
group (Fig. 6E). Treatment of the mice with GEM-conjugated redox-
sensitive micelles or miR-519c–complexed micelles showed a significantly less -SMA–positive fibrotic area (Fig. 6E). However,
the mice treated with the combination therapy showed the least
-SMA–positive staining in the tumor.
Ki-67 protein is an excellent marker for determining the cell
proliferation. Ki-67 staining of tumor tissues confirmed the extensive cell proliferation in the nontreated control group compared
to the free GEM-treated group. Tumor tissues treated with GEM-
conjugated redox-sensitive micelles–treated group showed a significantly lower number of cells Ki-67–positive cells (Fig. 6E). Furthermore,
cleaved caspase-3 staining of tumor tissues indicated the induction
of significant apoptosis by treatment with GEM redox-sensitive
micelles and miR-519c micelles–treated groups, compared to free
GEM- and saline-treated group. GE11 peptide–decorated combination
micelles–treated group showed the lowest Ki-67 and highest cleaved
caspase-3 expression compared to all other treatment groups (Fig. 6E).
In addition, we determined the systemic toxicity of GE11-decorated
combination micelles–treated groups and saline-treated control group
by histological analysis of the major organs. There were no noticeable histological changes observed in the livers, spleens, kidneys,
and hearts from the treatment groups (fig. S9), suggesting that the
mice tolerated GE11 peptide–decorated combination micellar formulation of GEM and miR-519c treatment well.
These findings indicated that EGFR-targeted micelles were able
to deliver miR-519c and GEM to the tumor sites and release the
antitumor agents via redox responsiveness, thus resulting in maximum synergy against pancreatic cancer without additional toxicities.
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GSH (Fig. 5F), thus reducing toxicity to normal tissues, and enhanced
stability of miRNA. Moreover, PEG shell can prevent aggregation
and impart a high degree of stability and stealth effect, leading to the
enhanced mean residence time of the drug and miRNA.
EGFR expression plays an important role in metastasis, especially
liver metastasis, and recurrence of human pancreatic cancer (34).
EGFR facilitates metastasis in pancreatic cancer through activation
of Akt and extracellular signal–regulated kinase pathway. Metastatic nodules have higher EFGR expression level than the primary
tumor, but we did not observe those nodules in the liver, as evidenced by H&E staining (Fig. 6E). The total mass balance of the
injected dose might be the reason for lower accumulation of GE11
combination micelles in the liver than the nontarget micelles (fig. S8,
A and B).
The rationale of combination therapy that combines two or
more therapeutic agents is to lower the doses of individual drug
and miRNA to achieve better therapeutic outcome and minimize
dose-related side effects (36). Since miR-519c resensitizes pancreatic cancer cells to GEM, we decreased the dose of GEM from 40 to
20 mg/kg and the dose of OMe-PS–miR-519c from 2 to 1 mg/kg
when used in combination to determine whether there is synergism
in their therapeutic efficacy. GEM-conjugated OMe-PS–miR-519c–
complexed mixed micelles exhibited the highest synergy in tumor
regression after systemic administration in orthotopic pancreatic
tumor–bearing mice (Fig. 6, B and C), with no weight loss (Fig. 6D)
or any sign of toxicity in the vital organs of mice from any group
during or after the treatment. We observed a significant decrease in
HIF-1, -SMA, and Ki-67 expression and a decrease in the cleaved
caspase-3 expressions in the combination treatment group (Fig. 6E).
This might be attributed to GE11 peptide–decorated micelles achieving higher concentrations of GEM and OMe-PS–miR-519c in the
tumor. High -SMA in pancreatic cancer is associated with dense
stroma reaction and worse patient outcome. -SMA is expressed by
activated PSCs, in response to hypoxia and Hh signaling.
Particle size distribution, shape, and surface morphology of nano
particles affect their biodistribution and accumulation at the tumor
site (37, 38). The particle size distribution of mPEG-co-P(Asp)g-TEPA-g-DC/miR-519c–complexed micelles, GEM-conjugated
mPEG-co-P(Asp)-g-Ala-S-S-GEM-g-DC micelles, and their combination micelles was 100 ± 20 nm (Fig. 5, C and D). On the basis of
our previous studies (2, 39), small particle size and PEGylated surface prolong the blood circulation of these micelles after systemic
administration. However, stroma acts as a barrier for nanoparticle
delivery to the pancreatic tumor. Since miR-519c targets hypoxia
and reduces the desmoplastic barrier, we observed a decrease in
-SMA expression in the tumor (Fig. 6E). Therefore, there was
significant accumulation of miR-519c and GEM in the tumor after
systemic administration of combination micelles (Fig. 6A and fig. S8C).
The combination of GEM and miR-519c showed a synergistic
effect in the nonmetastatic orthotopic desmoplastic pancreatic cancer mouse model (Fig. 6), which suggests that this treatment could
be useful for patients with stage 0 to III pancreatic cancer. Although
we did not observe liver metastasis during the therapeutic study,
EGFR expression is expected to be higher in hepatic metastatic nodules than in the primary tumor. Hence, GE11-based nanoparticle
delivery platform has the potential to target the metastatic nodules in the
liver or other distant metastasis in stage IV (34). More data related
to the therapeutic effect study in the orthotopic pancreatic tumor mouse
model of liver metastasis will be needed to testify this in the future.
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resistance. Over the decades, researchers faced the technical hurdles
associated with bringing a therapeutic oligonucleotide product to
market. A key hurdle includes getting small interfering RNA/miRNA
molecules into the right cells in vivo. Delivery of miRNAs is difficult
because they are relatively large, chemically unstable, immunogenic, and negatively charged molecules that do not cross the cell
membrane (32). Previously, we have shown that rationally designed
chemically modified miRNA could provide an excellent solution by
increasing their stability and decreasing their immunogenicity (18).
Here, we chemically modified miR-519c with OMe-PS at its 3′ end
to enhance stability, in vivo half-life, and loading affinity into the
RISC (Fig. 4).
The therapeutic efficacy of GEM depends on its delivery to the
tumor site, activation by dC kinase to GEM monophosphate, and
evading deactivation by cytidine deaminase. As discussed above in
detail, desmoplasia makes it difficult for GEM to achieve adequate
accumulation inside the tumor after systemic administration. Previously, we have shown that PEGylation prolongs the circulation
of GEM-conjugated micelles and improves its overall therapeutic
effect (14).
EGFR overexpression is observed in pancreatic cancer cells (33).
EGFR-binding monoclonal antibody cetuximab (C225) blocks the
binding of EGFR ligands to the receptor. Although cetuximab can exert
an anticancer effect in patients expressing wild-type KRAS, pancreatic
cancer that expresses mutated KRAS (Kirsten rat sarcoma) in 95% of cases
is resistant to cetuximab therapy. EGFR expression is also high in
distant metastatic pancreatic cancer (34), hence provides an ideal
candidate for targeted drug delivery. Previously, we demonstrated
higher tumor accumulation when cetuximab-conjugated micelles were
administered into orthotopic PC (pancreatic cancer)–bearing NSG mice,
which resulted in low tumor burden compared to immunoglobulin
G–targeted and nontargeted micelles (21). To avoid high mitogenic
potential of full-length EGFR antibody cetuximab, we developed
GE11 peptide (CYHWYGYTPQNVI)–decorated micelles, reported
equal target binding capacity as of cetuximab, and showed higher
drug accumulation and better efficacy (35). Further, small-sized
PEGylated nanoparticles and micelles are preferentially accurate
at the tumor and inflammatory sites via passive targeting (2).
To further improve our delivery system, here, we developed a
new redox-sensitive therapeutic strategy to enhance the chemotherapeutic efficacy in pancreatic cancer, while reducing systemic
side effects at the same time. GEM conjugated with the polymer via
an amide bond shows very slow release from the micelles, thus
proved to be a bottleneck for effective drug concentration. A conjugate with disulfide bonds, which can be easily cleaved by reducing
GSH into sulfhydryl groups, causes the degradation of micelles and
facilitates the release of the drug. The disulfide bond in mPEG-coP(Asp)-g-Ala-SS-GEM-g-DC can be readily broken by GSH, the
concentration of which is significantly higher in tumor than the
normal tissues. That can facilitate the precise release of GEM in
the tumor site and limit its toxicity to normal organs.
For codelivery, we synthesized mPEG-co-P(Asp)-g-DC-g-S-SGEM, mPEG-P(Asp)-g-TEPA-g-DC, and GE11-PEG-P(Asp)-g-DC
to load GEM and miR-519c in the hydrophobic core (Fig. 5). Because
of the complexity of different components, we formulated mixed
micelles using different ratios of these polymers. Our novel formulations offer distinct advantages such as targeted delivery of GEM
and miR-519c, prevention of rapid deamination of GEM, and the
intratumoral release of GEM based on intracellular stimuli such as
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In conclusion, the key hurdles of the clinical translation of nanomedicine are biological barriers, large-scale manufacturing, biocompatibility, and safety (40, 41). The characterization of our
combination micelles shows sufficient drug loading of GEM and
miRNA, redox-responsive release of GEM, and controlled release of
miRNA. The GE11-targeting mixed micelle system proposed in this
study leads to active EGFR targeting, significant accumulation in
desmoplastic pancreatic tumor, precise release of GEM and miR519c at tumor sites with the disulfide bond, and efficient synergistic
therapeutic effect in vivo. In addition, the PEG corona prolonged
the circulation time of micelles and has no observed toxicity in
major organs, which enhance the biocompatibility and safety of this
platform. Further, scale-up of this delivery system is feasible and
can support a first-in-human phase 1 clinical trial.
MATERIALS AND METHODS

Materials
Dulbecco’s modified Eagle’s medium (DMEM) high-glucose medium,
0.25% trypsin, and Dulbecco’s phosphate-buffered saline (DPBS) were
purchased from HyClone (Logan, UT). Keratinocyte-SFM (serum-free
medium) medium, bovine pituitary extract, and human recombinant
EGF were purchased from Gibco (Chevy Chase, MD). Heat-inactivated
FBS, antibiotic-antimycotic for cell culture, radioimmunoprecipitation assay (RIPA) buffer for cell lysis and phosphatase inhibitor cocktail (100×), live and dead assay kit, miR-519c-3p mimics, Pierce BCA
(bicinchoninic acid) protein assay kit, RediPlate 96 RiboGreen RNA
quantitation kit, and FxCycle PI/RNase staining solution (F10797)
were purchased from Thermo Fisher Scientific (Waltham, MA).
Hepes buffer was purchased from Millipore Sigma (St. Louis, MO).
Human c-Myc primary antibody was purchased from Proteintech
(Manchester, UK). GLUT1, GLI1, SHH, -actin, and SMO primary
antibodies were purchased from Santa Cruz Biotechnology (Dallas,
Xin et al., Sci. Adv. 2020; 6 : eabd6764
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TX). Laemmli buffer (4×), 10× tris/glycine/SDS protein electrophoresis running buffer (pH 8.3), and 10× tris-buffered saline buffer were
purchased from Bio-Rad (Hercules, CA). HIF-1 and ABCG2 primary antibodies were purchased from Abcam (Cambridge, MA). HIF-1
primary antibody was purchased from Novus Biologicals LLC (Centennial, CO). AGO2 primary antibody was purchased from Boster Bio
(Pleasanton, CA). Glucose uptake cell-based assay kit (item no. 600470)
was purchased from Cayman Chemicals (Ann Arbor, MI). RNeasy
mini kit, miScipt II RT kit, miScript SYBR Green kit, Hs_miR-519c-3p
miScript primer assay, and Hs_RnU6 miScript primer assay were
purchased from QIAGEN (Germantown, MD).
Cell culture
MIA PaCa-2 cell line was purchased from the American Type
Culture Collection (Manassas, VA), and MIA PaCa-2–resistant
(MIA PaCa-2R) cells were generated from MIA PaCa-2 by incubating with GEM in a high-glucose DMEM supplemented with 10%
FBS and 1% penicillin/streptomycin at 37°C, 5% CO2, and 100%
humidity and were split when confluent. HPDE cells were cultured
in Keratinocyte-SFM–supplemented bovine pituitary extract and
human recombinant EGF in an identical atmosphere. hPSCs were
cultured in stellate cell basal medium supplemented with 10% FBS,
stellate cell growth supplement, and 1% penicillin/streptomycin. A
hypoxic chamber filled with 94% nitrogen, 5% CO2, 1% O2, and
100% humidity was used to generate hypoxic conditions as needed.
hPSC-conditioned medium was obtained using the following
steps: Subconfluent PSCs were washed with PBS and incubated with
stellate cell basal medium under above conditions for 48 hours.
Then, the medium was collected and centrifuged for further use.
Cell migration assay
MIA PaCa-2R cells of 5 × 105 per well were seeded in six-well plate,
and, after 24 hours, cells were treated with PBS, scrambled miRNA,
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Fig. 7. Synthesis schemes of redox-sensitive GEM-conjugated copolymer, TEPA-containing polymer for complex formation with miRNA, and EGFR-targeting
GE11 peptide–conjugated polymer. GE11 peptide, CYHWYGYTPQNVI. (A) Synthesis of BLA-NCA. (B) Synthesis of mPEG-PBLA. (C-F) Synthesis of Ala-SS-GEM.
(G) Synthesis of mPEG-co-P(Asp)-g-Ala-SS-GEM-g-DC and mPEG-P(Asp)-g-TEPA-g-DC. (H) Synthesis of GE11-PEG-co-P(Asp)-g-DC. rt: room temperature, EDC:
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, HoBt: Hydroxybenzotriazole, TEA: triethylamine.
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and miR-519c with or without PSC-conditioned medium for 6 hours
under normoxia and hypoxia, respectively. Then, 1 × 105 cells were
collected from each well, resuspended with 200 l of serum-free
DMEM, and added to Transwell upper chambers. One milliliter of
DMEM containing 20% FBS that served as the chemoattractant was
in the lower chamber, and the cells were incubated for 24 hours
under normoxic and hypoxic conditions. A cotton-tipped swab was
used to remove the cells that did not migrate through the pores.
The chambers were fixed in 4% paraformaldehyde and stained with
crystal violet.

RT–quantitative PCR and Western blot
MIA PaCa-2R cells at a dose of 2 × 105 per well were plated in a
six-well plate overnight and transfected by Lipofectamine/miR-519c
under normoxic and hypoxic conditions for 24 hours. Then, all
samples were subjected to total RNA isolation by QIAGEN RNeasy
mini kit. Reverse transcription PCR was carried out using QIAGEN
miScript II reverse transcription kit. MiR-519c and mRNA levels of
SHH, GLI1, NME4, LDHA, HKII and TKT were quantitatively assayed in Roche Light Cycler 480 using miScript SYBR Green PCR
kit. MiR-519c and mRNA were normalized to U6 small nuclear RNA
and glyceraldehyde-3-phosphate dehydrogenase levels, respectively.
Primers were designed as follows: HKII-1, 5′-GAGCCACCACTCACCCTACT-3′ (forward) and 5′-ACCCAAAGCACACACGGAAGTT-3′ (reverse); TKT-1, 5′-TCCACACCATGCGCTACAAG-3′
(forward) and 5′-CAAGTCGGAGCTGATCTTCCT-3′ (reverse);
NME4-1, 5′-AGGGTACAATGTCGTCCGC-3′ (forward) and 5′-GACGCTGAAGTCACCCCTTAT-3′ (reverse).
For Western blot assay, all samples were isolated with RIPA
buffer on ice within 5 min to prevent HIF-1 degradation when
reexposed to O2, and the protein concentration was determined
with Pierce BCA protein assay kit. After that, cell lysates were mixed
with Laemmli loading buffer, boiled at 100°C for 5 min, loaded in
the wells of 4 to 15% SDS–polyacrylamide gel electrophoresis gel,
transferred by electroporation to polyvinylidene difluoride membrane,
Xin et al., Sci. Adv. 2020; 6 : eabd6764
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Cell cycle analysis
MIA PaCa-2R cells at a dose of 2 × 105 per well were plated in a sixwell plate and treated with scrambled miRNA and miR-519c under
normoxic and hypoxic conditions for 24 hours. Then, cells were
harvested, fixed with 70% ethanol in 4°C for 1.5 hours, and washed
three times with PBS to remove ethanol. Subsequently, cells were
centrifuged, a pellet of cells was collected in tubes, and 0.5 ml of
FxCycle PI/RNase staining solution was added to each flow cytometry sample for 30 min at room temperature, avoiding any exposure
to light. Flow cytometry was used to test samples at an excitation/
emission of 532/585 nm.
Cytotoxicity, apoptosis, and efficacy in desmoplastic tumor
spheroid model
Cytotoxicity of GEM, miR-519, and their combination was determined
by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide) assay. MIA PaCa-2R cells were plated at a density of 5000 cells
per well in a 96-well plate overnight. Then, GEM, miR-519c-3p, and
the combination of GEM and miR-519c were added to 96-well plates
with a GEM concentration ranging from 0.1 to 50 M and miR-519c
concentration from 5 to 100 nM under hypoxic condition. After 48 hours
of incubation, MTT solution at a concentration of 5 mg/ml was added,
and cells were cultured for another 3 hours. The supernatant was discarded, and 200 l of DMSO was added to each well. Cell viability was
determined using a spectrophotometer.
hPSC and MIA PaCa-2R cells (1:2; a total of 600 cells in 40 l per
well) in DMEM with 10% FBS were seeded onto Perfecta3D 96-Well
Hanging Drop Plates (3D Biomatrix Inc., Ann Arbor MI) and incubated with 5% CO2 at 37°C. On the fourth day, the spheroids were
treated with GEM, miR-519c, and their combination. Cells treated
with PBS and scrambled miRNA were used as controls. Morphologies
of tumor spheroids were observed under a Zeiss microscope on
days 6, 8, 10, and 12 to determine cytotoxicity. Live and dead assay
kit was applied following the manufacturer’s protocol to visualize
the apoptosis in desmoplastic tumor spheroids by confocal laser
scanning microscopy.
AGO2 association
Targeting gene silencing by RNA interference requires RISC. AGO
protein is a core protein binding to miRNA. We loaded AGO2 with
miRNAs by the action of a specialized assembly RISC-loading
complex. To assess the difference of miRNA loading between
unmodified miR-519c and OMe-PS–miR-519c, MIA PaCa-2R cells
at a dose of 2 × 105 per well were seeded in a six-well plate and then
transfected with unmodified miR-519c and OMe-PS–miR-519c
using Lipofectamine for 24 hours under normoxic and hypoxic
conditions. Cells were washed three times with PBS and lysed using
Pierce IP lysis buffer. A Pierce BCA assay kit was applied to quantify
protein concentration, and all samples were diluted to 1000 g/ml
by cell lysis buffer. Ten micrograms of AGO2 primary antibody and
500 l of cell lysis buffer were mixed and incubated overnight at
4°C. Then, the antigen sample/antibody mixture was added to 1.5 ml
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Glucose uptake assay and GLUT1 expression
MIA PaCa-2R cells of 5 × 104 per well were seeded in a 96-well plate.
After 24 hours, cells were treated with miR-519c and scrambled miRNA
in 100 l of glucose-free culture media for another 24 hours under normoxic and hypoxic conditions. Glucose uptake cell-based assay kit was
applied to evaluate glucose uptake in MIA PaCa-2R cells as following:
2-NBDG (2-deoxy-2-((7-nitro-2,1,3-benzoxadiazol-4-yl)amino)-glucose)
(150 g/ml) was added in glucose-free medium for 1.5 hours under normoxic and hypoxic conditions. The plates were centrifuged for 5 min at
400g at room temperature. The supernatants were discarded, and 200 l
of the cell-based assay buffer was added to each well for washing cells
twice. At the end, 100 l of cell-based assay buffer was added, and the
plates were analyzed by a fluorescent reader with an excitation/emission
of 485/535 nm to quantify 2-NBDG taken up by cells. Samples were
normalized by the fluorescence intensity in scrambled miRNA under
normoxia. The concentration of dCTP was quantified by LC-MS/MS.
For GLUT1 expression, MIA PaCa-2R cells at a dose of 2 × 105
per well were seeded in a six-well plate. After 24 hours, cells were
incubated under normoxic and hypoxic conditions. Then, cells were
harvested, washed with cell staining buffer three times, incubated
with GLUT1 primary antibody in cell staining buffer for 1 hour,
followed by Cy5-conjugated secondary antibody for another 30 min,
and analyzed by flow cytometer.

and incubated with blocking buffer for 1 hour at room temperature
first and then with anti–HIF-1, anti–c-Myc, anti-ABCG2, anti–
HIF-1, and anti–-actin primary antibody overnight at 4°C. IR-680
fluorescent dye–labeled secondary antibodies were added, followed
by imaging in iBright FL1000. HIF-1 and -actin were both used as
the loading control.
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of microcentrifuge tubes containing prewashed magnetic beads and
incubated for 1 hour at room temperature. After that, beads were
collected with a magnetic stand and washed twice with tris-buffered
saline and ultrapure water, respectively. One hundred microliters
of elution buffer was incubated with samples for 10 min at room
temperature. The supernatant of miRNA-AGO2 complexes was
harvested after separating from beads with a magnetic stand,
following which 15 l of neutralization buffer was added. Synthetic miR-39 from Caenorhabditis elegans (Cel-miR-39) was
selected as a spike-in control for miRNA quantification by RT–
quantitative PCR. For this purpose, first, all samples were isolated
by QIAGEN RNeasy mini kit, then reverse transcribed by miScript
II RT kit, and amplified with miScript SYBR Green PCR kit using
Roche LightCycler 480.
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Preparation and characterization of micelles and drug
release profile
The mixture of mPEG-co-P(Asp)-g-TEPA-g-DC and mPEG-coP(Asp)-g-Ala-SS-GEM-g-DC copolymers dissolved in acetone/
methanol (1:1, v/v) was added drop by drop to aqueous solution
containing miR-519c. To remove residual acetone and methanol,
samples were evaporated in a rotary evaporator. The mixture was
filtered through polycarbonate syringe filters of 200-nm pore size.
Particle size was measured using Malvern Zetasizer. In vitro GEM
release from redox-responsive micelles was performed under pH 7.4
with or without 10 mM GSH. Dialysis bags (molecular weight cutoff, 3500 Da) were loaded with 1 ml of redox-responsive micelles,
immersed into 30 ml of PBS buffer solutions, and shaken at a speed
of 100 rpm at 37°C (n = 3). GEM concentration was determined by
HPLC-UV under the following conditions: C18 column (5 m, 250 ×
4.6 mm), flow rate (1 ml/min), acetonitirle and water (90:10, v/v) as
mobile phase, an injection volume of 20 l, and a wavelength of
267 nm. In vitro miRNA release from TEPA micelles was carried
out by suspending the formulation to PBS buffer solutions under
pH 7.4 at each time point and shaking at a speed of 100 rpm at 37°C
(n = 3). The samples were centrifuged, and the supernatants were
collected at each time point. The concentration of released miRNA
was tested by RiboGreen RNA quantification kit.
Biodistribution and therapeutic studies
All the animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of Nebraska
Medical Center, Omaha, NE and carried out as per the National
Institutes of Health guidelines. The orthotopic human pancreatic
cancer mouse model was developed using 6- to 8-week-old male
NSG mice (20 to 25 g). Luciferase stably expressing MIA PaCa-2R
cells (0.5 × 106) and hPSCs (0.5 × 106) were mixed with Matrigel
(2:1) using ice-cold instruments and syringes. Then, mice were
anesthetized using isoflurane in an induction chamber, and 30 l
of Matrigel cell suspension was orthotopically injected into the pancreas tail. Tumor growth was monitored using the Spectrum IVIS
(PerkinElmer, Hopkinton, MA) after intraperitoneal administration
of luciferin (20 mg/ml) (150 l per mouse). Three weeks after tumor
injection, free GEM and OMe-PS–miR-519c, combination micelles,
and GE11 combination micelles were injected to mice via the tail
vein as a single administration at a dose (or dose equivalent) of
GEM (20 mg/kg) and miR-519c (1 mg/kg). Mice were euthanized
either at 6 or 24 hours, and major organs such as the tumor, heart,
liver, spleen, lung, and kidney were collected for LC-MS/MS analysis (4000 QTRAP, AB, Sciex Inc.). Briefly, 50 mg of tissue samples
were homogenized in 1 ml of PBS, spiked with 5-aza-dC as the internal standard and transferred on ice immediately. Subsequently,
3.0 ml of cold acetonitrile was added, followed by vortexing and
high-speed centrifugation in 4°C. The supernatant was evaporated
to dryness, and the residues were reconstituted with 200 l of acetonitrile:water (10:90, v/v). LC-MS/MS data acquisition will be performed
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Synthesis of redox-responsive GEM-conjugated copolymer,
TEPA-containing copolymer, and GE11 peptide–conjugated
copolymer
Redox-responsive GEM-conjugated copolymer, TEPA-containing
copolymer for complex formation with miRNA, and EGFR-targeting
GE11 peptide–conjugated copolymer were synthesized, as illustrated
in Fig. 7 as described below:
Step 1: Synthesis of BLA-NCA: We synthesized -benzyl l-aspartate
N-carboxy anhydride (BLA-NCA) by reacting l-aspartic acid -benzyl
ester with triphosgene in tetrahydrofuran (THF) under N2 atmosphere.
(Fig. 7A).
Step 2: Synthesis of amphiphilic polyamino copolymer mPEGP(Asp): We synthesized mPEG-PBLA by ring-opening polymerization of BLA-NCA using mPEG-NH2 (weight-average molecular
weight, 5000) as a macroinitiator in dry N,N-dimethylformamide at
55°C under the N2 atmosphere for 48 hours (Fig. 7B).
Step 3: Synthesis of Ala-SS-GEM: We synthesized Ala-SS-GEM
using the following four steps: First, Boc--Ala-OH was reacted
with bis(2-hydroxyethyl) disulfide using dicyclohexylcarbodiimide
(DCC) coupling reaction in the presence of 4-dimethylaminopyridine
in THF. The crude product was purified by flash column chromatography to obtain the intermediate Boc-Ala-SS-OH as a colorless
liquid (Fig. 7C). Second, Diboc-GEM was synthesized by reacting
GEM HCl, and Boc-anhydride was dissolved in a mixture of dioxane
and 1.0 M KOH at room temperature. After completion of the reaction,
the reaction mixture was extracted with EtOAc (Ethyl acetate) and
washed; dried organic layer was concentrated and, again, treated with Boc-
anhydride in 1.0 M KOH solution. After completion of the reaction,
the mixture was washed and dried, and the combined organic layer
was evaporated and purified by column chromatography to give
diboc-GEM a white solid product (Fig. 7D). Third, the intermediate
Boc-Ala-SS-OH and diboc-GEM were reacted with triphosgene in
the presence of pyridine in anhydrous dichloromethane (DCM) for
1 hour at 0°C. The reaction mixture was stirred for additional 4 hours
at room temperature. The crude product was then purified using
column chromatography to afford Boc-Ala-SS-Diboc-GEM as a
colorless oil (Fig. 7E). Last, Ala-SS-GEM was synthesized by removing the Boc groups in a mixture of DCM:trifluoroacetic acid (TFA)
(1:1) (Fig. 7F).
Step 4: Ala-SS-GEM and DC (DC-NH2) were conjugated to mPEG-
PBLA polymer by aminolysis reaction in dry dimethylformamide at
room temperature for 48 hours to afford mPEG-co-P(Asp)-g-AlaSS-GEM-g-DC (Fig. 7G). The structure and molecular weight of
mPEG-co-P(Asp)-g-Ala-SS-GEM-g-DC was determined by 1H NMR

and gel permeation chromatography, respectively. Similarly, mPEG-
P(Asp)-g-TEPA-g-DC was synthesized by replacing Ala-SS-GEM
with TEPA.
Step 5: GE11 peptide (CYHWYGYTPQNVI) and DC were conjugated to MAL-PEG-PBLA polymer in dry dimethylformamide
at room temperature overnight to get GE11-PEG-co-P(Asp)-g-DC
(GE11-targeting peptide; Fig. 7H).
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using the Analyst software on a QTRAP 4000 mass spectrometer.
The mass spectrometer will be operated in the positively selected
reaction monitoring for GEM [mass/charge ratio (m/z), 264.0/112.0)
and internal standard (m/z, 229.0/113.0). Total RNA from tissue
samples were isolated by QIAGEN RNeasy mini kit, and RT-PCR
assay was applied for miR-519c quantification.
For therapeutic study, mice were randomly divided into six groups
(n = 5 per group) when the bioluminescence reached 1 × 106. GEM
at a dose of 40 mg/kg for free GEM and GEM micelles, miR-519c at
the dose of 2 mg/kg for miR-519c micelles, and GEM at a dose of
20 mg/kg and miR-519c at 1 mg/kg for combination micelles were
administered via tail vein every 3 days in a total of five injections.
Body weights were measured before each dose administration.
Three days after the fifth administration, the animals were euthanized to harvest major organs such as the tumor, heart, liver, spleen,
lung, and kidney. Examination included H&E staining, immunohistochemical, and Western blot analyses.

SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/46/eabd6764/DC1
View/request a protocol for this paper from Bio-protocol.
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